Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 133Recurrence 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms, Plasma Cell 15Neoplasms 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 7Immunoglobulin Light-chain Amyloidosis 7Lymphoma, Non-Hodgkin 6Amyloidosis 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Hematologic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Burkitt Lymphoma 5Paraproteinemias 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Blood Protein Disorders 4Neoplasm Metastasis 3Myelodysplastic Syndromes 3Lymphoma, B-Cell 3Lung Neoplasms 3Esophageal Neoplasms 3Corneal Diseases 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2

Interventions

pembrolizumab 2Cyclophosphamide 2siltuximab 1ruxolitinib 1ricolinostat 1repotrectinib 1pralsetinib 1ponatinib 1pomalidomide 1pamiparib 1fludarabine 1ficlatuzumab 1enzalutamide 1blinatumomab 1Taxes 1Radiation 1Pemetrexed 1Paclitaxel 1Gefitinib 1Drug Therapy 1Dexamethasone 1Cisplatin 1CPI-0610 1Bortezomib 1Biopsy 1Bevacizumab 1Bendamustine Hydrochloride 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms by Histologic Type × Dexamethasone × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡